Titanocene Y

After initial clinical trials against breast and renal-cell cancer were performed with this compound,[3][4] the search for improved derivatives started.

[9][10] The compound is transported via serum albumin selectively into cancer cells[11][12] and targets their DNA by coordinating strongly to phosphate groups.

[15] Very encouraging is the fact that Titanocene Y is breaking platinum-resistance in human colon and human lung cancer cells,[16] which might make it attractive as a cytotoxic component of future 2nd or 3rd line cancer treatments.

[20] Titanocene Y can be given in the mouse in high dosages and it shows generally mild toxicity in the form of diarrhea.

Titanocene Y is not patent protected and would therefore benefit from non-commercial sponsoring to develop it into a cytotoxic drug candidate for the treatment of advanced renal-cell cancer – an area in need of better therapies.